China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- China's State FDA cleared Simcere Pharmaceutical Group's new drug application for Iremod (iguratimod) for rheumatoid arthritis, in the world's first approval of the compound, Simcere announced Aug. 25
You may also be interested in...
BMS Ties Up With Simcere To Commercialize Orencia SC In China
Looking for differentiated products in an increasingly tough pricing environment, Simcere will help Bristol bring its first biologic to China.
Three Times The Charm? BMS Ties Up With Simcere To Commercialize Orencia SC In China
Looking for differentiated products in an increasingly tough pricing environment, Simcere will help Bristol bring its first biologic to China.
Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.